TransCode Therapeutics, Inc. (RNAZ) vs Vivos Therapeutics, Inc. (VVOS)
A side-by-side comparison of TransCode Therapeutics, Inc. and Vivos Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
RNAZ
TransCode Therapeutics, Inc.
$1.73HealthcareDelayed quote: Oct 6, 2026, 2:42 PM EDT
VVOS
Vivos Therapeutics, Inc.
$0.16HealthcareDelayed quote: Oct 6, 2026, 2:42 PM EDT
Total return — RNAZ vs VVOS
growth of $100 · dividends reinvested · last 5yRNAZ -100.0% (-94.2%/yr)VVOS -99.9% (-73.7%/yr)VVOS compounded faster over this window
Log scale — wide-divergence pair
RNAZ VVOS
RNAZ vs VVOS: by the numbers
- •VVOS is the larger company ($2M vs $2M market cap).
- •Both run net losses; RNAZ's is the smaller (0.00% vs -122.42% net margin).
Metrics side by side
Valuation
| Metric | RNAZ | VVOS |
|---|---|---|
| P/S ratio | N/A | 0.10 |
Profitability
| Metric | RNAZ | VVOS |
|---|---|---|
| Gross margin | 0.00% | 59.72% |
| Operating margin | 0.00% | -107.92% |
| Net margin | 0.00% | -122.42% |
| ROE | -30.92% | N/A |
| ROIC | -23.73% | -182.30% |
Growth (annualized)
| Metric | RNAZ | VVOS |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 7.52% |
| Total return CAGR (5Y) | -93.39% | -72.60% |
Frequently asked
- How have RNAZ and VVOS total returns compared?
- Over the past 5 years, RNAZ delivered -93.39% and VVOS delivered -72.60% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.